Sartorius Stedim Biotech SA (DIM)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 210.60 |
|---|---|
| 52-week range | 150.00 – 225.00 |
| Return, 1 month / 3 months | +2.4% / +28.4% |
| Return, 1 year / 3 years | −0.0% / +22.8% |
| Trend | Uptrend |
| RSI (14) | 52 |
| Volatility (1 year) | 39.7% |
| Worst drawdown (1 year) | -31.8% |
| Average daily value traded | 17.84M EUR |
| Dividend yield | 0.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sartorius Stedim Biotech makes equipment and consumables used in the manufacture of biological medicines. Its products include single-use bioreactors, filtration systems, tubing, bags and other components that drug makers use to grow cells and purify treatments. Customers are mainly pharmaceutical and biotechnology companies that produce vaccines, antibodies and other biologics. The company is based in France and operates as part of the wider Sartorius group, supplying laboratories and production plants around the world.
On this site Sartorius Stedim Biotech SA appears as a stock on the Euronext Paris (France), code DIM, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sartorius Stedim Biotech SA (DIM) trades on the Euronext Paris in France. It last closed at EUR 210.60 on 23 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 66 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 0.0% and over the last three months it rose 28.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 15.7% | ||
| From 52-week high | -5.6% | ||
| Momentum | 80 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 28.4% | ||
| 6-month return | 33.4% | ||
| 12-month return, skipping the last month | -2.4% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -31.8% | ||
| Liquidity | 93 · Strong | Trades actively. | |
| Average daily value traded | 17.84M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 30 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.3% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −2.0% |
|---|---|
| 1 month | +2.4% |
| 3 months | +28.4% |
| 6 months | +33.4% |
| 1 year | −0.0% |
| 3 years | +22.8% |
| 5 years | −55.2% |
Signals
| 50-day / 200-day average | 201.87 / 182.00 |
|---|---|
| Golden / death cross (60 days) | Golden, 32 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.17 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 31 Mar 2026 | EUR 0.6900 |
| 2 Apr 2025 | EUR 0.6900 |
| 2 Apr 2024 | EUR 0.6900 |
| 30 Mar 2023 | EUR 1.4400 |
| 31 Mar 2022 | EUR 1.2600 |
| 29 Mar 2021 | EUR 0.6800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.